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Background: Activation of the renin-angiotensin-aldosterone system adversely affects arterial compliance, and arterial stiffness increases in the 
presence of chronic hypertension. We hypothesized that aldosterone antagonism with spironolactone therapy improves aortic stiffness in patients 
with resistant hypertension.
Methods: 26 patients, age 55 ± 1.3 years, with resistant hypertension defined as BP >140/90 mm Hg at 2 clinic visits despite use of at least 
3 antihypertensive medications (duration of hypertension 18 ± 2 years) underwent ECG-gated cine Cardiac MRI (CMR; 1.5 T; reconstructed to 32 
cardiac phases per RR cycle; typical in-plane resolution 1.5 x 1.5 mm) to evaluate aortic stiffness. CMR was performed at initiation of the study 
(baseline; BL) in a modified transverse plane intersecting the ascending aorta. The cross-sectional area of the ascending aorta was measured using 
semi-automated aortic contour detection; the pulsatility (% change in aortic cross section area from smallest diastolic area to largest systolic area) 
and distensibility (pulsatility/pulse pressure) were measured from these areas. BP was measured just before and after CMR and the pulse pressure 
averaged from the two measurements. Spironolactone was then added at 25 mg/d and titrated up to 50 mg/d at 4 weeks. Other antihypertensive 
medications were discontinued as needed to maintain constant BP. Patients underwent repeat CMR at 6 months (6MO).
Results: There was significant increase in aortic pulsatility (BL 17 ± 7, 6MO 21 ± 7%; p = 0.01 by 2-tailed paired t-test) and distensibility (BL= 
0.28 ± 0.11, 6MO= 0.38 ± 0.14; p = 0.008) after 6 months therapy with spironolactone, indicating a reduction in aortic stiffness. Blood pressure 
did not change over the course of the study (systolic 143.8 ± 17.7 mmHg at BL, 140.3 ± 23.1 at 6MO; diastolic 83.8 ± 12.7 at BL, 82.2 ± 13.8 at 
6MO; p = NS for all).
Conclusions: Spironolactone therapy induces rapid improvement in aortic stiffness within 6 months of therapy in patients with resistant 
hypertension. CMR allows easy, semi-automated assessment of aortic stiffness, along with other measures of cardiovascular function, in a routine 
examination and with minimal post-processing and analysis.
